Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 6/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474475 | 0.89 | ALDH1A1 (0.39) | CYP2C19CYP2C9POLBGPR139TSHR | |
| SCHEMBL6474360 | 0.85 | CYP2C19 (0.50) | CYP2C19CYP2C9POLBGPR139TSHR | |
| SCHEMBL7313887 | 0.83 | CYP2C19 (0.46) | CYP2C19CYP2C9POLBGPR139TSHR | |
| SCHEMBL7301560 | 0.76 | CYP2C19 (0.48) | CYP2C19CYP2C9POLBGPR139TSHR | |
| SCHEMBL6474348 | 0.74 | ALDH1A1 (0.44) | CYP2C19POLBGPR139TSHRNPC1 | |
| SCHEMBL6474507 | 0.72 | KDM4E (0.41) | KDM4EALDH1A1HSD17B10GAA | |
| SCHEMBL7303747 | 0.71 | TNF (0.38) | CYP2C19CYP2C9GPR139KDM4EHSD17B10 | |
| SCHEMBL30209304 | 0.70 | CYP1A2 (0.46) | CYP2C19CYP2C9NPC1KDM4EALDH1A1 | |
| SCHEMBL215875 | 0.69 | SMN1; SMN2 (0.45) | CYP2C19CYP2C9POLBTSHRHTT | |
| SCHEMBL31518503 | 0.69 | SMN1; SMN2 (0.44) | CYP2C19CYP2C9POLBTSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854140-B1 | Vitronectin receptor antagonists, their production and their use | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-11-06 | — | — | EP | disclosed |
| US-6867208-B2 | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 2005-03-15 | — | — | US | disclosed |
| US-20030027807-A1 | Vitronectin receptor antagonists, their preparation and their use | GENENTECH, INC. AND HOECHST AKTIENGESELLSCHAFT | 2003-02-06 | — | — | US | disclosed |
| US-6387895-B1 | BONE DISORDERS; CARDIOVASCULAR DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-05-14 | — | — | US | disclosed |
| US-6207663-B1 | AS INHIBITORS OF BONE RESORPTION, TUMOR GROWTH, TUMOR METASTASIS, OR INFLAMMATION, OR FOR THE TREATMENT OR PROPHYLAXIS OF CARDIOVASCULAR DISORDERS, NEPHROPATHIES OR RETINOPATHIES | HOECHST ATKIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| US-6011045-A | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027807-A1 | Vitronectin receptor antagonists, their preparation and their use | ADGRF1, ADGRE5, BSG | CYP2C19 2513/4885CYP2C9 3291/4885POLB 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.